

CHAMPIONS ONCOLOGY, INC.
Form 8-K
November 01, 2016

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): October 28, 2016

CHAMPIONS ONCOLOGY, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-11504	52-1401755
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

1 University Plaza, Suite 307, Hackensack, New Jersey 07601
(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: (201) 808-8400

Not applicable
(Former Name or Former Address if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

INFORMATION TO BE INCLUDED IN THE REPORT

Item Departure of Directors or Certain Officer; Election of Directors; Appointment of Certain Officer;
5.02. Compensatory Arrangements of Certain Officers.

On October 28, 2016, Champions Oncology, Inc. (the “Company”) extended the initial employment agreements dated November 5, 2013 between the Company and each of Joel Ackerman, Chief Executive Officer, and Ronnie Morris, President. The extensions are for 1 year and provide that each of Mr. Ackerman and Mr. Morris shall be compensated \$325,000 in the form of stock options. All other terms and conditions of the agreements remain.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

CHAMPIONS
ONCOLOGY, INC.
(Registrant)

Date: November 1, 2016 By: /s/ Joel Ackerman
Joel Ackerman
Chief Executive Officer